Introduction Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intra-and interobserver variability is an important concern.
STRENGTHS AND LIMITATIONS OF THIS STUDY
-For the first time the diagnostic performance of an automated computer guided PASI measurement will be evaluated on a large scale in daily clinical routine.
-The primary and secondary objectives of this study address open questions of major importance for future clinical trials using PASI measurements.
-A "golden standard" for PASI measurements is lacking. Therefore, all statistical analyses can only provide insight into differences of the level of concordance and reproducibility between PASI calculations by physicians and the computer algorithm.
-Limitations of this study are the non-randomized and single-site setting
INTRODUCTION

Background and preliminary work
Psoriasis is a chronic, inflammatory skin disease that affects 1.5% to 2 % of the population in Western industrialized countries. Without adequate treatment, patients with psoriasis experience a high burden of disease and a substantial restriction in quality of life [1] . Plaque psoriasis is the most common clinical form of the disease and is characterized by sharply demarcated erythrosquamous plaques which most frequently occur on the extensor sides of the extremities [1] . Assessment of disease progress is performed by means of the Psoriasis Area and Severity Index (PASI). Accurate severity scoring in psoriasis is of paramount importance for determination of a medical indication for systemic therapy and the subsequent surveillance of treatment efficacy. Furthermore, considerable significance is given concerning the use of PASI calculations in the context of clinical trials investigating new pharmaceutical for patient inclusion in these trials. Secondly, the assessment of the efficacy of any investigational drug in psoriasis treatment is mostly expressed by the percentage of reduction of the baseline PASI. Thus, PASI calculations represent an important measure to achieve regulatory approval for marketing of anti-psoriatic drugs. The most widely established tool and current standard for measuring the severity and extent of psoriasis is the Psoriasis Area and Severity Index (PASI) [2] . The PASI assessment is based on a complex calculation including the percentage of the body area covered by psoriatic lesions, the extent of erythema, scaling, and thickness of psoriatic plaques. For the scoring, the body is divided into the four anatomical regions head, trunk, upper and lower extremities. Both the severity of psoriatic skin lesions and the extent of the covered body surface are calculated separately. Erythema, induration, and scaling are each measured on a 0-4 visual analogue scale and the involved body surface area (BSA) is measured using a 0-6 visual analogue scale. The PASI score varies from 0 to 72. Higher scores indicate more severe disease manifestations. A 75% reduction of the baseline PASI (PASI 75) was suggested as a current benchmark for many antipsoriatic drugs under investigation in clinical trials [3] . The primary endpoint in these trials calculates the percentage of patients reaching PASI 75 after a certain time interval under treatment with the investigational drug. The PASI was developed by Fredriksson and Pettersson in 1978 as an objective means to measure the effectiveness of a retinoid during the course of the study [4] . In several subsequent studies it became apparent that the BSA measurement is the major limitation of the PASI. In most cases the involved body surface was significantly overestimated by physicians and noticeable variations between the assessors were observed. Even trained and experienced personnel showed a lack of concordance in scoring the extent of psoriasis in the same patient [5] [6] [7] [8] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   5 Reliable and accurate assessment of disease severity in psoriasis is of utmost importance in order to evaluate the indication for systemic treatment or treatment efficacy in daily clinical practice. Moreover, in the course of clinical trials PASI measurements are the most important indicator for patient inclusion and the evaluation of treatment efficacy of the investigational drug. To date, the most extensively studied and validated assessments tool is the PASI, which, therefore, represents the current standard. However, PASI calculations can be tedious and subjective. A major limitation of the PASI is that it is not routinely used by many clinicians and high inter-and intraobserver variability is an important concern. Several studies have
Rationale of the study
shown that especially the involved body surface is often overestimated and that even experienced raters have difficulty in rating the area of involvement. In conclusion, there is a great need for a standardized and objective method for a reproducible PASI calculation.
DESIGN/METHODS
Study design
This is a retrospective, single-center, non-interventional study to evaluate an automated computer guided PASI measurement by digital image analysis of 120 patients suffering from plaque psoriasis in comparison to conventional PASI assessments by physicians.
Study objectives
The primary objective of this study is the comparison of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary endpoints include i) the statistical assessment of physicians' interobserver variance in PASI calculations, ii) the statistical assessment of physicians' intraobserver variance in PASI assessments of the same patients'
images after a time interval of at least 4 weeks, iii) the statistical assessment of variance between physicians' prospective versus retrospective PASI calculations, iv) the reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one timepoint.
Study population and criteria for inclusion/exclusion
One hundred twenty patients suffering from plaque psoriasis, undergoing medical treatment at the Department of Dermatology, University of Heidelberg and at least 18 years of age will be included in this study. Patients with other clinical types of psoriasis e.g. erythrodermic or pustular psoriasis shall be excluded from this study.
Methods
The prospective PASI calculation is performed during regular consultation and physical examination of the patient by a trained physician (PASI 1). Directly afterwards, total body imaging with the FotoFinder Automated Total Body Mapping (ATBM)® system will be performed. Digital images will then be used for automated computer guided measurements of PASI (computerized PASI) with the approved FotoFinder PASI Software for Psoriasis Quantification (PASIvision®). Automated Total Body Mapping and computerized PASI measurements will be done twice consecutively for measurement of consistency and reproducibility. Next, three other PASI-trained physicians will assess the PASI based on the analysis of the total body images (PASI 2-4) for measurement of inter-individual consistency.
Additionally, a repeated PASI calculation of the same images at least 4 weeks after first calculation by the identical three physicians (PASI 5-7) will be done for measurement of intraindividual consistency (see figure 1 ). seamless data downloads to common statistical packages and procedures for importing data from external sources [10] . The individual values of the PASI will be directly entered in the REDCap database by the physicians during evaluation of the total body images. After PASI data for all patients has been entered by the three physicians (PASI 2-4) the database will be locked for 4 weeks and PASI assessments can then be repeated (PASI 5-7) at the earliest availability of the three physicians. The time interval of at least 4 weeks between the two assessments is sufficiently long to exclude that physicians remember earlier PASI scorings of the 120 patients. Physician will have neither access to their previously entered data nor to PASI scores of other physicians.
Statistical considerations
Sample size calculation
This is a retrospective non-interventional analysis of digital images of 120 patients with plaque psoriasis. Only descriptive statistics will be applied. The general objective of this study is not proving superiority of one method over the other, but to evaluate concordance and reproducibility of PASI calculations. Due to feasibility reasons, a sample size of 120 fully evaluable patient datasets will be collected. This sample size is sufficient to assess the performance of the computer algorithm as well as inter-and intra-observer variability [11] .
Statistical analysis
All PASI score results will be analyzed descriptively by tabulation of the mean and standard deviation, medians, and first and third quartiles, as well as minimum and maximum. The intra-class correlation coefficient measuring the agreement between computerized PASI versus physicians' PASI, the reproducibility of computerized PASI, and the inter-rater as well as intra-rater reliability will be calculated. Bland-Altman plots will be created to visualize the agreement of the values. Mean bias and limits of agreement will be calculated.
Ethical considerations and regulatory obligations
The information contained in this protocol and the implementation of the study is consistent at the University of Heidelberg and current treatment guidelines. This implies that the presented study does not require any direct patient related procedures. The names of patients and all confidential data are subject to professional discretion and the "Bundesdatenschutzgesetz (BDSG)". Processing of medical data will only take place in pseudonymous form. Third persons will not be allowed access to patient data. There is no personal benefit and no additional risks for study participants.
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ABSTRACT
Introduction Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intra-and inter-observer variability is an important concern.
Therefore, there is a great need for a standardized and objective method that guarantees a reproducible PASI calculation. Within this study we will investigate the precision and reproducibility of automated, computer-guided PASI measurements in comparison to trained physicians to address these limitations. 
Methods and analysis
STRENGTHS AND LIMITATIONS OF THIS STUDY
INTRODUCTION
Background and preliminary work
Psoriasis is a chronic, inflammatory skin disease that affects 1.5% to 2 % of the population in Western industrialized countries. Without adequate treatment, patients with psoriasis experience a high burden of disease and a substantial restriction in quality of life [1] . Plaque psoriasis is the most common clinical form of the disease and is characterized by sharply demarcated erythrosquamous plaques which most frequently occur on the extensor sides of the extremities [1] . Assessment of disease progress is performed by means of the Psoriasis Area and Severity Index (PASI). Accurate severity scoring in psoriasis is of paramount importance for determination of a medical indication for systemic therapy and the subsequent retinoid during the course of the study [3] . In several subsequent studies it became apparent that the BSA measurement is one of the major limitations of the PASI. Besides the 'rule of nine' the BSA calculation was often based on the 'one hand method' since it was assumed that the area of a flat patients' hand represents 1% of his total BSA [4] . In most cases the involved body surface was significantly overestimated by physicians and noticeable variations between the assessors were observed. Even trained and experienced personnel showed a lack of concordance in scoring the extent of psoriasis in the same patient [5] [6] [7] [8] . Meanwhile, it has been shown that one hand actually represents 0.70-0.76% of the BSA which might be one possible explanation for surface overestimation [9] . Additionally, time pressure during the consultation is undoubtedly another important influence on the high intra-and inter-observer variability. Of note, PASI is not taking relevant patient reported outcomes such as pain and itch into account. Therefore, several alternative scores for psoriasis severity assessment were implemented more recently [10] . For example an innovative and alternative severity score based on the dermoscopic vascular pattern of psoriatic skin lesions was suggested by
Carlesimo et al. [11] . Finally, a further limitation of the PASI is that it is not routinely used by many clinicians. However, PASI allows for historical comparisons between clinical trials evaluating different anti-psoriatic drugs and will therefore still be widely applied.
Rationale of the study
A reproducible, standardized and objective assessment of disease severity in psoriasis is of utmost importance in order to evaluate the indication for systemic treatment or treatment efficacy in daily clinical practice. To date, the most extensively studied and validated assessments tool is the PASI, which, therefore, represents the current standard. However, significant concerns arise from PASI's inherent level of subjectivity and high inter-and intraobserver variability. Therefore, within this study we will investigate the precision and reproducibility of automated, computer-guided PASI measurements in comparison to trained physicians.
DESIGN/METHODS
Study design
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Study objectives
The primary objective of this study is to investigate the precision of automated computer guided PASI measurements by means of digital image analysis versus conventional, prospective or retrospective physicians' PASI assessments. Secondary endpoints include i) the statistical assessment of physicians' inter-observer variance in PASI calculations, ii) the statistical assessment of physicians' intra-observer variance in PASI assessments of the same patients' images after a time interval of at least 4 weeks, iii) the statistical assessment of variance between physicians' prospective versus retrospective PASI calculations, iv) the reproducibility of automated computer guided PASI measurements by assessment of two sets of total body digital images of the same patients taken at one time point.
Study population and criteria for inclusion/exclusion
Methods
The prospective PASI calculation will be performed during regular consultation and physical examination of the patient by a trained physician (pPASI 1). Directly afterwards, total body imaging with the FotoFinder Automated Total Body Mapping (ATBM)® system will be performed (ATBI 1+2). Digital images will then be used for automated computer guided 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Capture (REDCap) tool. REDCap is a secure, web-based application designed to support data capture for research studies providing an intuitive interface for validated data entry, audit trails for tracking data manipulation and export procedures, automated export procedures for seamless data downloads to common statistical packages and procedures for importing data from external sources [13] . The individual values of the PASI will be directly entered in the REDCap database by the physicians during evaluation of the total body images. After PASI 1-3 ) the database will be locked for 4 weeks and PASI assessments can then be repeated (rPASI 4-6) at the earliest availability of the three physicians. The time interval of at least 4 weeks between the two assessments is sufficiently long to exclude that physicians remember earlier PASI scorings of the 120 patients. Physician will have neither access to their previously entered data nor to PASI scores of other physicians or to the computerized PASI scores.
Statistical considerations
Sample size calculation
This is a retrospective non-interventional analysis of digital images of 120 patients with plaque psoriasis. Only descriptive statistics will be applied. The general objective of this study is not proving superiority of one method over the other, but to evaluate concordance and reproducibility of PASI calculations. Due to feasibility reasons, a sample size of 120 fully evaluable patient datasets will be collected. This sample size is sufficient to assess the performance of the computer algorithm as well as inter-and intra-observer variability [14] .
Statistical analysis
All PASI score results will be analyzed descriptively by tabulation of the mean and standard deviation. The Intraclass-Correlation-Coefficient (ICC) will be used to measure the agreement between computerized and physicians' PASI, the reproducibility of computerized PASI and the inter-rater and intra-rater reliability. Bland-Altman plots will be used to visualize the agreements. Mean bias between the PASI measurements and limits of agreement will be calculated. The analyses will be carried out using R (V3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Processing of medical data will only take place in pseudonymous form. Third persons will not be allowed access to patient data. There is no personal benefit and no additional risks for study participants. The design and the final results of the study will be published and made available to the public in the form of congress presentations, press releases, and manuscripts Protection Act (BDSG). Study records will be kept for 10 years.
FOOTNOTES
Funding statement
Study registration
Conflicts of interest
The authors declared that they have no competing interests. Flowchart of the study. At the first consultation each patient will be examined by a PASI trained physician (P1) who will prospectively attain pPASI 1. Each patient will then be send for automated total body imaging (ATBI) and calculation of the computerized PASI (cPASI 1+2) by automated computer-guided PASI measurements (ACPM). ATBI and ACPM will be done twice consecutively for measurement of consistency and reproducibility. The digital pictures of the total body imaging will After at least 4 weeks the same three physicians will perform a second assessment of the total body images and calculate rPASI 4-6. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
